Royalty Report: Drugs, Disease, Genome – Collection: 233427

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 6

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 6

Primary Industries

  • Drugs
  • Disease
  • Genome
  • Therapeutic
  • Delivery
  • DNA
  • Drug Discovery
  • Diagnostic
  • Multiple Sclerosis

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233427

License Grant
Licensor grants an exclusive worldwide license (with the right to grant sublicenses) under Licensor Licensed Intellectual Property to research, develop, make, have made, use, import, export, offer to sell and sell Licensed Products in the Field.

Licensor grants a non-exclusive, perpetual, worldwide, sublicensable license to Licensor Improvements and the claims of any Licensor Patent covering such Licensor Improvements, but only to the extent that such claims cover  Licensor Improvements.

License Property
Licensor technology shall mean Cytofectin Delivery Technology, Direct Injection Technology and DNA Process Technology.

Product shall mean any product or part thereof, the manufacture, use or sale of which is covered in whole or in part by a valid claim.

DNA Process Technology shall mean all patentable or unpatentable inventions, discoveries, technology and information of any type whatsoever, including without limitation compositions, methods, processes, confidential information, technical information, knowledge, experience and know-how regarding technologies related to the manufacture and processing of plasmid DNA for human use; in each case, which is owned by or licensed to Licensor on the Effective Date or during the term of this Agreement, all to the extent and only to the extent that Licensor now has or will have during the term of this Agreement the right to grant licenses, immunities or other rights thereunder.

Cytofectin Delivery Technology shall mean all patentable or unpatentable inventions, discoveries, technology and information of any type whatsoever, including without limitation compositions, methods, processes, confidential information, technical information, knowledge, experience and know-how, regarding the use of cytofectins in the delivery of genes into a patient for the treatment or prevention of one or more diseases or conditions; in each case which is owned by or licensed to Licensor on the Effective Date or during the term of this Agreement, all to the extent and only to the extent that Licensor now has or hereafter will have the right to grant licenses, immunities or other rights thereunder.

Direct Injection Technology shall mean all patentable or unpatentable inventions, discoveries, technology and information of any type whatsoever, including without limitation compositions, methods, processes, confidential information, technical information, knowledge, experience and know-how, regarding the direct injection of genes (including plasmid DNA-based delivery technology) into a patient to cause the In Vivo expression of a desired protein, thereby effecting delivery of such protein to a patient for the treatment or prevention of one or more diseases or conditions; in each case which is owned by or licensed to Licensor on the Effective Date or during the term of this Agreement, all to the extent and only to the extent that Licensor now has or will have during the term of this Agreement the right to grant licenses, immunities or other rights thereunder.

Field of Use
Field shall mean the intervention, treatment and/or prevention of a disease or disorder in humans by Gene Therapy.

Licensor's 'naked DNA delivery technology' allows genes to enter the body without being bundled with a virus.

IPSCIO Record ID: 128301

License Grant
For the Licensee products, Licensor grants a non-exclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensor Technology and Licensor Patents to perform research and preclinical development in the Field during the research term using Licensee research genes.

Licensor grants a non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee research genes exercisable during the research term of this Agreement.

Licensor grants an exclusive worldwide license, with the right to grant sublicenses, under Licensor Technology and Patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensors patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 203979

License Grant
Licensor grants a nonexclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensors technology and patents to perform research and preclinical development in the field during the research term using Licensee research genes.

Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.

With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license.  Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensed patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 256190

License Grant
The University grants an exclusive license with the right to grant sublicenses, with the right to grant further sublicenses, both subject to the terms and conditions of this Agreement, in the field of use and the territory to make, have made, import, use, market, offer for sale and sell Licensed Products and to practice Licensed Processes.
License Property
The patent is for Plasmids suitable for gene therapy.
Field of Use
The field of use means all fields.  The Licensee researches and develops biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

IPSCIO Record ID: 239025

License Grant
With this amendment, where Licensee desires Licensor to generate Knock-Out Mice and ES Cell Lines for Licensee based on human gene sequences provided by Licensee and then to analyze such Knock-Out Mice and ES Cell Lines, the licensed products have been updated regarding restricted rights projects, and, adds patent information.

For the Exclusive License under Licensor Pre-Existing Patents and Know-How and Restricted Rights Project Patents and Know-How for the Research, Development and Commercialization of Licensed Products,  Licensor grants an exclusive, even as to Licensor, world-wide right and license under the Licensor Pre-Existing Patents and Know-How, and, to the extent specified in the Parties designation(s) of Restricted Rights Project(s), an exclusive, even as to Licensor, or non-exclusive, world-wide right and license under the Restricted Rights Project Patents and Know-How, in each case to research, develop, make (or have made), use, sell, offer for sale, and import Licensed Products in the Field.

For the License under Licensor Pre-Existing Patents and Know-How and Restricted Rights Project Patents and Know-How for the Research, Development and Commercialization of Products Other than Licensed Products in the Field,  Licensor grants a worldwide right and license under the Licensor Pre-Existing Patents and Know-How and, to the extent specified in the Parties designation(s) of Restricted Rights Project(s), the Restricted Rights Project Patents and Know-How to research, develop, make (or have made), use, offer for sale, sell, and import products, including, but not limited to Small Molecule Drugs, other than Licensed Products for use in the Field.

For the Non-Exclusive Research License Grant under Licensor Knock-Out Technology to Knock-Out Mice and Progeny,  Licensor grants a worldwide, non-exclusive right and license under the Licensor Knock-Out Technology to use, breed, cross-breed and have bred and cross-bred KnockOut Mice and Progeny, at the internal research facilities of Licensee and its Academic Collaborators or Contract Service Providers, for research directed toward the discovery, identification, selection, characterization, development or commercialization of products for use in the Field.

License Property
Patent is for Isogenic DNA.
U.S. Patent No. 5,789,215 issued August 4, 1998 entitled 'Gene Targeting in Animal Cells Using Isogenic DNA Constructs'

Licensor possesses certain knowledge and experience in the design, generation, and phenotypic analysis of Knock-Out Mice and ES Cell Lines.

Restricted Rights Project means a Project involving a Project Gene which is subject to the exclusive rights Licensor  has granted to a Third Person prior to the initial proposal of such Project Gene by Genentech.

Licensor Knock-Out Technology means all Patents and Know How which are owned, controlled or licensed by Licensor as of the Effective Date or created or acquired by Licensor during the course of this Agreement and related to a process or method used in the creation or generation of Knock-Out or transgenic mice, including the process for creating Knock-Out Mice and Overexpression Mice.

Licensed Product means a pharmaceutical preparation other than a Small Molecule Drug that is ready for administration to the ultimate consumer and that contains as the active pharmaceutical ingredient a Protein Candidate or that directly modulates a Protein Candidate, or the gene that encodes a Protein Candidate.

Field of Use
Licensor established a drug discovery alliance with Licensee to discover novel therapeutic proteins and antibody targets based on its isogenic DNA gene targeting technology.

Field means any human or animal healthcare applications including, without limitation, the diagnosis, prevention and treatment of diseases or conditions.

IPSCIO Record ID: 203405

License Grant
Licensor grants to the German Licensee an exclusive worldwide, sub-licensable license under the Licensor Intellectual Property, to do or have done research on use, develop, have developed, make and have made, sell, offer for sale, import and distribute Interferon Beta gene Products in the Field.

Licensee shall have an option to obtain an exclusive worldwide, sub-licensable license under the Licensor Intellectual Property, to do or have done research on, use, develop, have developed, make and have made, sell, offer for sale, import and distribute Gene X Products in the Field.

Licensee shall have another option to obtain a non-exclusive, worldwide, sub-licensable license under the PINC Intellectual Property, to do or have done research on, use, develop, have developed, make and have made, sell, offer for sale, import and distribute NOS Products in the Field.

License Property
The proprietary PINCâ„¢ polymer-based delivery technologies provide more consistent levels of gene expression and enhance transfection efficiency of plasmid DNA delivered intramuscularly or intratumorally. Our gene delivery technologies have been used in various clinical candidates, and formulations can be optimized for specific DNA vaccine delivery needs.

The GeneSwitch®  gene regulation system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function.

Device shall mean, individually or collectively, as the case may be, the electroporation generator used for the electrically assisted delivery of Products and/or the disposable applicator.

PINC Technology means Licensor proprietary polymeric transfection facilitating agents which, when formulated with nucleic acids, do not condense the nucleic acids.

NOS means Licensors proprietary mutant endothelial constitutive nitric oxide synthetase gene.

The PINC patents are for Formulated Nucleic Acid Compositions and Methods of Administering the Same for Gene Therapy; Improved Poloxamer Compositions for Nucleic Acid Delivery; and Nucleic Acid Compositions and Methods of Administration for Gene Therapy.

The GENESWITCH® patents are for Progesterone Receptor Having C Terminal Hormone Binding Domain Truncations.

The patents relating to Electroporation include Injection and Electroporation Apparatus for Drug and Gene Delivery; and  Electroporation System with Voltage Control Feedback for Clinical Applications; and more.

Field of Use
Field means all preventive, therapeutic or diagnostic applications in humans.  This agreement is exclusive for the field of multiple sclerosis.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.